View Older Stories View More Recent Stories
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $472 at Raymond James
-
Alnylam Pharma (ALNY) Tops Q3 EPS by $2.38
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
Cantor Fitzgerald Reiterates Alnylam Pharmaceuticals (ALNY) at Neutral on Good Execution
-
Truist Securities: 'Is Biotech Back?!'
-
Biotech stocks: Q3 earnings preview
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $495 at Stifel
-
Alnylam secures $500 million revolving credit facility
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at RBC Capital
-
Alnylam joins Alliance for Genomic Discovery genomic dataset
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $470 at BMO Capital
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $470 at BMO Capital
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Truist Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Piper Sandler: 'Alnylam Pharmaceuticals (ALNY) Continues to Impress'
-
Why public perception matters so much for biotech valuations
-
Truist Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) Ahead of ESC Data Presentation
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Wolfe Research Upgrades Alnylam Pharmaceuticals (ALNY) to Peerperform
-
Oppenheimer Upgrades Alnylam Pharmaceuticals (ALNY) to Outperform
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $550 at UBS
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $450 at Scotiabank
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $450 at BMO Capital
-
Alnylam Pharma (ALNY) Tops Q2 EPS by 91c
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $389 at Bernstein SocGen Group
-
Raymond James Assumes Alnylam Pharmaceuticals (ALNY) at Outperform
-
Truist Securities Starts Alnylam Pharmaceuticals (ALNY) at Buy
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $290 at Cantor Fitzgerald
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $348 at JPMorgan
-
Jefferies Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Goldman rolls out latest U.S. Conviction List update
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $377 at Needham
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $360 at BMO Capital
-
Alnylam Pharma (ALNY) names Pushkal Garg as Chief Research and Development Officer
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Amvuttra Survey Suggests 2Q Beat'
-
Instil Bio Inc. (TIL) Appoints John Maraganore to its Board
-
Alnylam Pharma (ALNY) Receives EU Approval for AMVUTTRA
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'HQ Visit Makes Us More Positive About The Q'
-
JPMorgan Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 92c
-
Alnylam Pharma (ALNY) Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

